Search results for "RAS system"

showing 1 items of 1 documents

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

2009

The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective …

DrugACE inhibitorsmedia_common.quotation_subjectPharmaceutical Sciencelcsh:Medicinelcsh:RS1-441ReviewPharmacologylcsh:Pharmacy and materia medicachemistry.chemical_compoundRAS systemDiabetes mellitusDrug DiscoveryRenin–angiotensin systemmedicinecardiovascular diseasesmedia_commonbusiness.industrylcsh:RAliskirenmedicine.diseaseangiotensin receptor blockerschemistryPathophysiology of hypertensionHeart failureMolecular MedicineAngiotensin Receptor BlockersbusinessaliskirenKidney diseasePharmaceuticals
researchProduct